Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Open Access
- 15 January 2024
- journal article
- review article
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-18
Abstract
Immunotherapy has rapidly evolved in the past decades in the battle against cancer. Chimeric antigen receptor (CAR)-engineered T cells have demonstrated significant success in certain hematologic malignancies, although they still face certain limitations, including high costs and toxic effects. Natural killer cells (NK cells), as a vital component of the immune system, serve as the “first responders” in the context of cancer development. In this literature review, we provide an updated understanding of NK cell development, functions, and their applications in disease therapy. Furthermore, we explore the rationale for utilizing engineered NK cell therapies, such as CAR-NK cells, and discuss the differences between CAR-T and CAR-NK cells. We also provide insights into the key elements and strategies involved in CAR design for engineered NK cells. In addition, we highlight the challenges currently encountered and discuss the future directions in NK cell research and utilization, including pre-clinical investigations and ongoing clinical trials. Based on the outstanding antitumor potential of NK cells, it is highly likely that they will lead to groundbreaking advancements in cancer treatment in the future.Keywords
Funding Information
- National Natural Science Foundation of China (82260038)
- Natural Science Foundation of Yunnan Province (202201AT070198)
This publication has 159 references indexed in Scilit:
- Natural killer cell biology: An update and future directionsJournal of Allergy and Clinical Immunology, 2013
- Engineering lymph node homing of ex vivo–expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7Blood, 2012
- High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutationHaematologica, 2011
- A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human MelanomasCancer Research, 2010
- Engineering lymphocyte subsets: tools, trials and tribulationsNature Reviews Immunology, 2009
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral methodCancer Gene Therapy, 2009
- Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating LymphocytesHuman Gene Therapy, 2009
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomasProceedings of the National Academy of Sciences, 2008
- Hematopoiesis: An Evolving Paradigm for Stem Cell BiologyCell, 2008
- Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cellsBlood, 2005